Fig. 4

Effects of pamidronate on the kinetics of phosphorylated AKT, ERK1/2, and NF-κB p65 in bilirubin-impaired SHED. The results by western blot analysis were shown in Fig. 3. Relative phosphorylated expression of p-AKT (Ser) to AKT (a), p-AKT (Thr) to AKT (b), p-AKT (Ser) and p-AKT (Thr) [p-AKT (Ser+Thr)] to AKT (c), p-ERK1/2 to ERK1/2 (d), and p-NF-κB p65 to NF-κB p65 (e) was analyzed at each time point in each group. a–e B0, SHED treated with 0 μM bilirubin; B50, SHED treated with 50 μM bilirubin; B50+PAM, SHED treated with 50 μM bilirubin and 10 μM pamidronate. n = 5 for all groups. Statistical analysis was performed as described in the “Methods” section. Graph bars showed the means ± SEM. *P < 0.05 and ***P < 0.005. (vs. 0 h in each group). NS, no significance